A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum
Completed · Phase 2 · Has a placebo group
Conditions studied: Pseudoxanthoma Elasticum
In brief
This study was designed to evaluate the safety, tolerability, pharmacodynamics (PD) of DS-1211b, and pharmacokinetics (PK) in individuals with Pseudoxanthoma elasticum (PXE). PXE is a rare disease that is associated with significant risks of visual impairments and comorbidity from peripheral and cardiovascular diseases, and adversely impacts the quality of life in afflicted individuals.
Key facts
- Study ID
- NCT05569252
- Run by
- Daiichi Sankyo
- People needed
- 65
- Starts
- 2022-10-20
- Expected to finish
- 2023-11-21
- Last updated by the study team
- 2024-12-31
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mid-Atlantic Epilepsy and Sleep Center — Bethesda, Maryland, United States
- Boston Neuro Research Center — North Dartmouth, Massachusetts, United States
- Infinity Medical Research Inc — North Dartmouth, Massachusetts, United States
- Frontage Clinical Services, Inc. — Secaucus, New Jersey, United States
- Clinilabs — New York, New York, United States
- Clinical Research of Philadelphia, LLC — Philadelphia, Pennsylvania, United States
- UMC Utrecht — Utrecht, Netherlands
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.